Last reviewed · How we verify
recombinant 70-kD heat-shock protein — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
recombinant 70-kD heat-shock protein (recombinant 70-kD heat-shock protein) — Memorial Sloan Kettering Cancer Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| recombinant 70-kD heat-shock protein TARGET | recombinant 70-kD heat-shock protein | Memorial Sloan Kettering Cancer Center | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- recombinant 70-kD heat-shock protein CI watch — RSS
- recombinant 70-kD heat-shock protein CI watch — Atom
- recombinant 70-kD heat-shock protein CI watch — JSON
- recombinant 70-kD heat-shock protein alone — RSS
Cite this brief
Drug Landscape (2026). recombinant 70-kD heat-shock protein — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-70-kd-heat-shock-protein. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab